Singapore markets open in 5 hours 54 minutes

Novo Nordisk A/S (NONOF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
128.30+1.85 (+1.46%)
As of 02:22PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close126.46
Open127.41
Bid0.00 x 0
Ask0.00 x 0
Day's range125.00 - 130.75
52-week range74.70 - 140.32
Volume45,735
Avg. volume43,352
Market cap586.986B
Beta (5Y monthly)0.19
PE ratio (TTM)47.87
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.86 (1.47%)
Ex-dividend date22 Mar 2024
1y target estN/A
All
News
  • GlobeNewswire

    Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024

    Bagsværd, Denmark, 2 May 2024 - financial report for the period 1 January 2024 to 31 March 2024 Operating profit increased by 27% in Danish kroner and by 30% at constant exchange rates (CER) to DKK 31.8 billion. Sales in North America Operations increased by 34% in Danish kroner (35% at CER). Sales growth in the US was positively impacted by gross-to-net sales adjustments related to prior years. Sales in International Operations increased by 8% in Danish kroner (11% at CER).Sales within Diabetes

  • GlobeNewswire

    Novo Nordisk A/S - share repurchase programme

    Bagsværd, Denmark, 1 May 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme init

  • GlobeNewswire

    Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024

    Bagsværd, Denmark, 26 April 2024 – In accordance with Section 32 of the Danish Capital Markets Act, Novo Nordisk A/S is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred. Referring to Company Announcement no 32/2024 dated 24 April 2024, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk A/S as per 26 April 2024. Number of